U.S. Tech Hardware Stock News

NasdaqGS:GRAL
NasdaqGS:GRALBiotechs

What GRAIL (GRAL)'s FDA PMA Submission for Galleri Test Means For Shareholders

GRAIL, Inc. previously submitted the final module of its Premarket Approval application to the U.S. FDA for its Galleri multi-cancer early detection test, drawing on performance and safety data from the large PATHFINDER 2 and NHS-Galleri trials and supported by a bridging analysis to the updated test version. This milestone builds on the FDA’s earlier Breakthrough Device designation and centers on extensive real-world screening data to assess Galleri’s clinical utility. We’ll explore how...
NYSE:MTRN
NYSE:MTRNMetals and Mining

Is It Too Late To Consider Materion (MTRN) After Its Strong Share Price Run?

If you are trying to work out whether Materion’s share price still offers value at its current level, the key question is how that price lines up against what the business may be worth. The stock last closed at US$145.83, with returns of 2.8% over 7 days, 8.3% over 30 days, 13.5% year to date, 43.6% over 1 year, 73.7% over 3 years and 115.6% over 5 years. This naturally raises questions about how much of the story is already reflected in the price. Recent news coverage has focused on...
NasdaqGS:SFM
NasdaqGS:SFMConsumer Retailing

A Look At Sprouts Farmers Market (SFM) Valuation As It Enters The New York Market

New York entry: why Centereach matters for Sprouts Farmers Market (SFM) Sprouts Farmers Market (SFM) is entering New York with a new store in Centereach, Long Island, opening January 30. This expansion puts the grocer into a large, highly competitive food retail market. See our latest analysis for Sprouts Farmers Market. At a share price of US$66.34, Sprouts Farmers Market has recently seen a 4.52% 1 day share price decline and a 17.73% year to date share price decline. Its 1 year total...
NYSE:APTV
NYSE:APTVAuto Components

Weighing Aptiv (APTV) After Mixed Returns And Conflicting Valuation Signals

If you are wondering whether Aptiv's current share price lines up with its underlying value, you are not alone. This article is designed to help you frame that question clearly. Aptiv's stock last closed at US$79.72, with returns of 1.1% over 7 days, a 3.5% decline over 30 days, 1.6% year to date, a 25.6% gain over 1 year, and declines of 31.3% and 48.2% over 3 and 5 years respectively. Taken together, these figures give a mixed signal about growth potential and risk perception. Recent...
NYSE:GOLD
NYSE:GOLDRetail Distributors

Tether Goldcom Deal Connects Stablecoins With Physical Bullion Investors

Tether has invested in and partnered with Gold.com, the parent company of NYSE:GOLD, to integrate tokenized gold into its platform. The collaboration will allow customers to use stablecoins to purchase physical gold through Gold.com. The move links a major stablecoin issuer with a large gold company, connecting blockchain based assets with physical bullion markets. For investors watching NYSE:GOLD, this partnership sits at the crossroads of traditional commodities and digital assets...
NasdaqGM:GPCR
NasdaqGM:GPCRPharmaceuticals

Structure Therapeutics’ Oral Obesity Drug Enters Phase 2 As Investor Focus Grows

Structure Therapeutics (NasdaqGM:GPCR) has advanced its lead obesity candidate GSBR-1290 into phase 2 clinical trials as an oral treatment. The move comes as the company draws increased attention for targeting the obesity market with a pill-based approach rather than injectables. Analyst optimism and early discussion about potential takeovers have put fresh focus on the stock. Structure Therapeutics, trading under NasdaqGM:GPCR, is drawing fresh interest after pushing GSBR-1290 into phase...
NYSE:RH
NYSE:RHSpecialty Retail

Will RH’s (RH) Earnings Beat and Leadership Shift Reshape Its Experiential Luxury Narrative?

RH recently reported third-quarter 2025 results showing year-over-year revenue growth and continued market share gains, alongside progress in expanding its gallery footprint and experiential concepts such as the RH Interior Design office and RH Ocean Grill. A separate development saw the departure of Chief Gallery & Customer Officer Stefan Duban in January 2026, with his responsibilities redistributed across existing leadership, highlighting how RH aims to support its growth initiatives...
NasdaqGS:MKSI
NasdaqGS:MKSISemiconductor

Is MKS (MKSI) Quietly Rewriting Its Capital Structure For Greater Strategic Freedom?

MKS Inc. recently closed a private offering of €1.00 billion in 4.250% senior unsecured notes due 2034 and refinanced portions of its term loans and revolving credit facility, extending key maturities into the next decade and reducing interest margins on its dollar and euro borrowings. By replacing part of its secured term loan with unsecured notes and lowering interest costs, MKS has reshaped its capital structure in a way that may ease future financing pressure and improve financial...
NYSE:MOH
NYSE:MOHHealthcare

Has The Market Gone Too Far In Marking Down Molina Healthcare (MOH) Shares?

If you are trying to figure out whether Molina Healthcare's share price reflects its true worth, the starting point is understanding how its current market price compares with a range of valuation checks. The stock last closed at US$176.84, with returns of a 4.4% decline over 7 days, 4.3% decline over 30 days, 0.9% decline year to date, 38.0% decline over 1 year, 41.3% decline over 3 years, and 18.2% decline over 5 years, which may have shifted how investors see its potential and its...
NasdaqGS:QCOM
NasdaqGS:QCOMSemiconductor

Why QUALCOMM (QCOM) Is Down 10.5% After Record Q1 Results But Cautious Memory‑Supply Guidance

In early February 2026, Qualcomm reported record fiscal first‑quarter revenue of US$12.25 billion and net income of US$3.00 billion, but issued weaker second‑quarter guidance due to a global memory chip shortage constraining smartphone production. Alongside the earnings release, Qualcomm highlighted that strong demand for premium handsets and growing automotive and IoT contributions are being held back by supply bottlenecks rather than a lack of end‑market interest. We’ll now look at how...
NasdaqGS:TECH
NasdaqGS:TECHLife Sciences

Bio Techne (TECH) Margin Compression To 6.7% TTM Tests Bullish Growth Narratives

Bio-Techne (TECH) has reported Q2 2026 revenue of US$295.9 million with basic EPS of US$0.24, alongside trailing twelve month revenue of about US$1.2 billion and EPS of US$0.52, setting up a mixed picture for growth and profitability. The company has seen quarterly revenue move between US$289.5 million and US$317.0 million over the past six reported periods, while basic EPS has ranged from a loss of US$0.11 to a recent run rate just above US$0.24. This matters for investors focused on how...
NYSE:VYX
NYSE:VYXSoftware

Assessing NCR Voyix (VYX) Valuation After Prolonged Share Price Weakness

Why NCR Voyix (VYX) Is On Investors’ Radar Today NCR Voyix (VYX) is drawing fresh attention after a period of weak share performance, with the stock around $9.47 and total return figures over the past year and past 3 months reflecting double digit declines. With revenue of about $2.65b and a reported net loss of $62 million, investors are evaluating how this digital commerce business, focused on retailers and restaurants across multiple regions, is managing the balance between growth...
NYSE:TNC
NYSE:TNCMachinery

Tennant Sets 2026 Meeting Timeline As Undervalued Shares Show Steady Gains

Tennant Company set the date for its 2026 annual meeting of shareholders. The company also announced the deadline for shareholders to nominate director candidates for the 2026 board election. The update outlines the timetable that will guide board nominations and voting for NYSE:TNC. Tennant, trading on the NYSE under ticker NYSE:TNC, recently closed at $80.84. The stock is up 5.5% over the past week, 5.0% over the past month, and 9.3% year to date, while showing a 4.1% decline over the...
NYSE:PHIN
NYSE:PHINAuto Components

Assessing PHINIA (PHIN) Valuation After Recent Share Price Momentum And Conflicting Fair Value Signals

PHINIA: recent returns and earnings context PHINIA (PHIN) has attracted attention after a recent period of positive share price performance, with the stock showing gains over the past week, month and past 3 months alongside reported revenue and net income figures. See our latest analysis for PHINIA. At a latest share price of US$71.08, PHINIA has seen a firm build up in momentum, with a 33.16% 3 month share price return and a 44.23% 1 year total shareholder return. These figures point to...
NasdaqCM:ONDS
NasdaqCM:ONDSCommunications

Ondas (ONDS) Faces Short-Seller Scrutiny: Sustainable Strategy or Fragile Acquisition-Driven Growth Story?

In early February 2026, JCapital Research released a critical report on Ondas Holdings, questioning its acquisition-driven business model, reliance on share issuance for funding, and aspects of management governance and financial sustainability. This scrutiny landed just as Ondas was expanding its defense-focused autonomous systems footprint through the planned acquisition of UK-based Rotron Aero and new government drone contracts. We’ll now explore how JCapital’s critique of Ondas’...
NYSE:COUR
NYSE:COURConsumer Services

Coursera Udemy Merger Targets Cost Synergies And AI Focused Growth

Coursera (NYSE:COUR) has entered into a merger agreement with Udemy, combining two major online learning platforms. The companies outlined expected annual cost synergies and product fit across their course catalogs and learner bases. Management also highlighted plans to use AI native products and data driven tools across the combined platform. Coursera is coming into this merger with a share price of $5.98 and a mixed recent track record, including a 22.3% decline over the past year and a...
NYSE:RVTY
NYSE:RVTYLife Sciences

Assessing Revvity (RVTY) Valuation After New SLAS2026 Lab Automation Launches

What the SLAS2026 product launches mean for Revvity stock Revvity (RVTY) just used the SLAS2026 conference to roll out several new tools for high throughput drug discovery, including a high content screening system, a multimode plate reader, and an automated liquid handling workstation. For you as an investor, the focus is not the trade show itself, but what these launches say about how Revvity is trying to compete in automated, data heavy lab workflows that many pharma and biotech customers...
NasdaqGS:BNTX
NasdaqGS:BNTXBiotechs

BioNTech Hire Signals People Focus As Oncology Plans And Valuation Attract Attention

BioNTech (NasdaqGS:BNTX) has created a new Chief People Officer role. Kylie Jimenez has been appointed to the position, effective immediately. The move is tied to BioNTech’s goal of becoming a multi product oncology leader beyond its COVID 19 work. BioNTech, known widely for its COVID 19 vaccine partnership, is working to build a broader pipeline in oncology and other therapeutic areas. The new Chief People Officer role indicates that leadership views talent, organizational design, and...
NasdaqGS:ON
NasdaqGS:ONSemiconductor

Is ON Semiconductor (ON) Pricing In Recent End Market Headlines Too Generously?

If you are wondering whether ON Semiconductor's current share price reflects its true worth, this article will help you unpack what the numbers are saying about value. The stock last closed at US$63.10, with returns of 5.4% over 7 days, 2.0% over 30 days, 11.3% year to date, 23.1% over 1 year, a 24.7% decline over 3 years, and 52.9% over 5 years. Recent news coverage has focused on ON Semiconductor's role in key semiconductor end markets and how investors are weighing that against sector...
NYSE:OKLO
NYSE:OKLOElectric Utilities

Why Oklo (OKLO) Is Down 27.8% After Uranium Sector Weakness Clouds Its Fuel-Cost Assumptions And What's Next

In recent days, Oklo has come under pressure as analyst reports and sector-wide weakness in uranium and nuclear-energy names raised questions about how higher nuclear fuel costs and easing geopolitical risk premiums could affect its advanced reactor business model. At the same time, the company still benefits from substantial U.S. government support and large-scale tech partnerships, creating an unusual mix of perceived opportunity and execution risk for a pre-revenue nuclear...
NYSE:PRLB
NYSE:PRLBMachinery

Proto Labs (PRLB) Valuation Check After Recent Share Price Swings And Mixed Return Profile

Proto Labs (PRLB) is back on investor radars after recent share price swings, prompting a closer look at how its digital manufacturing business, profitability, and recent returns fit into a broader portfolio. See our latest analysis for Proto Labs. Recent moves have been mixed, with a 1 day share price return of a 1.83% decline and a 90 day share price return of 7.12%, while the 1 year total shareholder return of 18.22% hints at improving momentum despite a weaker 5 year total shareholder...
NYSE:MTD
NYSE:MTDLife Sciences

Should Mettler-Toledo’s Strong 2025 Results and 2026 Sales Outlook Require Action From MTD Investors?

Mettler-Toledo International Inc. recently reported its full-year 2025 results, with sales of US$4,026.40 million and net income of US$869.19 million, alongside higher basic and diluted earnings per share from continuing operations versus the prior year. The company also issued 2026 guidance calling for local currency sales increases in both the first quarter and full year, giving investors a clearer view of expected near-term business trends. Next, we’ll examine how Mettler-Toledo’s outlook...
NYSE:RTX
NYSE:RTXAerospace & Defense

Did Long-Term U.S. Missile Contracts Just Shift RTX's (RTX) Defense Modernization Investment Narrative?

Recently, Raytheon, an RTX business, entered into a series of long-term framework agreements with the U.S. Department of Defense to significantly expand production of key munitions including Tomahawk, AMRAAM, SM-3 and SM-6 missiles, backed by investments in facilities, technology and workforce over periods of up to seven years. The scale and duration of these missile production agreements highlight how deeply embedded RTX has become in U.S. defense modernization and high-volume weapons...